Moramide intermediate

Moramide intermediate

Clinical data
Trade names	β-Methyl-α,α-diphenyl-4-morpholinebutanoic acid
Other names	4-Morpholinebutanoic acid, β-methyl-α,α-diphenyl-, moramide intermediate
Routes of administration	N/A
ATC code	none
Legal status
Legal status	AU: S9 (Prohibited substance) BR: Class A1 (Narcotic drugs)[1] DE: Anlage II (Authorized trade only, not prescriptible) US: Schedule II UN: Narcotic Schedule I
Identifiers
IUPAC name 3-Methyl-4-morpholin-4-yl-2,2-diphenylbutanoic acid
CAS Number	3626-55-9
PubChem CID	567581
ChemSpider	493453
UNII	4O5ZQW8AMM
KEGG	C22688
CompTox Dashboard (EPA)	DTXSID401045346
Chemical and physical data
Formula	C21H25NO3
Molar mass	339.435 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(O)C(c1ccccc1)(c2ccccc2)C(C)CN3CCOCC3
InChI InChI=1S/C21H25NO3/c1-17(16-22-12-14-25-15-13-22)21(20(23)24,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17H,12-16H2,1H3,(H,23,24) Key:AWLNVHVUYACOMZ-UHFFFAOYSA-N

Moramide intermediate (β-Methyl-α,α-diphenyl-4-morpholinebutanoic acid, on INCB Yellow List as 2-methyl-3-morpholino-1,1-diphenylpropane carboxylic acid) is a moramide precursor scheduled by UN Single Convention on Narcotic Drugs.

In the United States, moramide intermediate is designated as a Schedule II controlled substance,^[2] and has an ACSCN of 9802. The 2014 annual manufacturing quota was nil.^[3]

In Australia, moramide intermediate is listed as a Schedule 9 (Prohibited Substance)^[4]